Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 10/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 9/20 | 0.38 |
| ▸ | LCK | P06239 | 6/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7020602 | 0.93 | MKNK1 (0.38) | MKNK1MKNK2LCKCDK2 | |
| SCHEMBL7018015 | 0.81 | LCK (0.43) | MAP3K14MKNK1MKNK2LCKCDK2 | |
| SCHEMBL7018022 | 0.81 | LCK (0.43) | MAP3K14MKNK1MKNK2LCKCDK2 | |
| SCHEMBL7016354 | 0.78 | MKNK1 (0.35) | MAP3K14MKNK1MKNK2LCKCDK2 | |
| SCHEMBL7020659 | 0.73 | MKNK1 (0.35) | MKNK1MKNK2LCKCDK2 | |
| SCHEMBL7017711 | 0.72 | MKNK2 (0.63) | MKNK1MKNK2LCK | |
| SCHEMBL7017709 | 0.70 | LCK (0.74) | MKNK1MKNK2LCK | |
| SCHEMBL7567370 | 0.68 | MAP3K14 (0.46) | MAP3K14MKNK1MKNK2LCKCDK2 | |
| SCHEMBL7020600 | 0.64 | MKNK2 (0.63) | MKNK1MKNK2LCK | |
| SCHEMBL7016932 | 0.64 | LCK (0.72) | MKNK1MKNK2LCKCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |